Industry

Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data for STX-721, a Next-Generation Exon 20 Mutant EGFR Inhibitor, at the EORTC-NCI-AACR Symposium 2022

 — STX-721 demonstrates potential best-in-class selectivity and strong anti-tumor activity across multiple EGFR and HER exon 20 mutant CDX and PDX models — — Investigational new drug (“IND”) application submission expected in 2023 — BOSTON–(BUSINESS WIRE)–Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, … [Read more…]

Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022

– XB002, a next-generation tissue factor-targeting antibody-drug conjugate, was well-tolerated at multiple dose levels – – Pharmacokinetic analysis confirmed XB002 was stable with low levels of free payload – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced promising initial results from the ongoing dose-escalation stage of JEWEL-101, a phase 1 study evaluating XB002, Exelixis’ next-generation … [Read more…]

EMD Serono Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment

Phase II clinical trial data of evobrutinib demonstrated low disease activity and stable EDSS, with NfL levels, a marker of neuronal injury, remaining low in people with RMS after three and a half years of therapy Late-breaking data showed evobrutinib-treated patients mounted an antibody response to mRNA COVID vaccinations similar to that of healthy subjects … [Read more…]

Merck Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment

Phase II clinical trial data of evobrutinib demonstrated low disease activity and stable EDSS, with NfL levels, a marker of neuronal injury, remaining low in people with RMS after three and a half years of therapy Late-breaking data showed evobrutinib-treated patients mounted an antibody response to mRNA COVID vaccinations similar to that of healthy subjects … [Read more…]

Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022

Sustained Improvement Observed in ATA188 Treated Patients Achieving Confirmed Disability Improvement (CDI) in Open Label Extension (OLE) with up to 46 Months Follow up Patients Treated with ATA188 that Achieved CDI Demonstrate Significantly Less Brain Atrophy in Longitudinal Analysis Through 42 Months All Patients in the OLE with Stable Disease Remained Stable for up to … [Read more…]

Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care

Company’s scientific leadership will be highlighted in 39 abstracts presented across its multiple sclerosis (MS) portfolio Data on investigational BTK inhibitor evobrutinib demonstrate long-term disease stability in people living with relapsing MS (RMS) Phase IV study highlights improvement in measures of Quality of Life in people living with RMS after two years of treatment with … [Read more…]

EMD Serono Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care

Company’s scientific leadership will be highlighted in 39 abstracts presented across its multiple sclerosis (MS) portfolio Data on investigational BTK inhibitor evobrutinib demonstrate long-term disease stability in people living with relapsing MS (RMS) Phase IV study highlights improvement in measures of Quality of Life in people living with RMS after two years of treatment with … [Read more…]

New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis

Retrospective analyses from the Phase 3 DAYBREAK open-label extension study showed more than 90% of participants who received Zeposia mounted a serologic response to COVID-19 vaccination All adverse events related to COVID-19 in vaccinated study participants were nonserious Data are among 13 abstracts being presented at ECTRIMS 2022 that further reinforce the safety and efficacy … [Read more…]

BIOCORP and NOVO NORDISK Strengthen Their Partnership With a New Agreement on Mallya® Smart Sensor

ISSOIRE, France–(BUSINESS WIRE)–#digitalhealth–Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, announces the signature of a partnership agreement with Novo Nordisk for the commercialization of Mallya, initially in Japan. This new agreement is reinforcing the partnership between Novo Nordisk and … [Read more…]

Dassault Systèmes Partners with Sanofi to Optimize Tech Transfer and Industrialization at Its Future “EVolutive Facilities”

Sanofi will use the 3DEXPERIENCE platform to design, implement, qualify and operate modular production lines at its new-generation “EVolutive Facilities” (EVF) in France and Singapore 3DEXPERIENCE platform models will enable Sanofi to generate virtual twins to drive the agility, reliability and performance of Sanofi’s new facilities Improved agility and flexibility will enable faster implementation of … [Read more…]